Drug Trial Radar · NCT04455750
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Oct 14, 2021
Primary completion
Mar 15, 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant). Enzalutamide helps fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as rucaparib, fight prostate cancer by prevent tumor cells from repairing their DNA. Giving enzalutamide and rucaparib may make patients live longer or prevent their cancer from growing or spreading for a longer time, or both. It may also help doctors learn if a mutation in any of the homologous recombination DNA repair genes is helpful to decide which treatment is best for the patient.
Conditions
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Interventions
EnzalutamideDrug
Given PO
Rucaparib camsylateDrug
Given PO
PlaceboDrug
Given PO
Leuprolide AcetateDrug
Given IM
Goserelin AcetateDrug
Given SC
DegarelixDrug
Given SC
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic progression-free survival (rPFS)Time frame: Up to 5 years post treatment
- Overall survival (OS)Time frame: Up to 5 years post treatment
Locations
414 sites in 1 country. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Cancer Center at Saint Joseph's
Phoenix, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Kaiser Permanente Dublin
Dublin, California
Kaiser Permanente-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Kaiser Permanente-Modesto
Modesto, California
Kaiser Permanente-Oakland
Oakland, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Roseville
Roseville, California
Kaiser Permanente Downtown Commons
Sacramento, California
Kaiser Permanente-South Sacramento
Sacramento, California
Sharp Memorial Hospital
San Diego, California
Kaiser Permanente-San Francisco
San Francisco, California
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California
Kaiser Permanente San Leandro
San Leandro, California
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, California
Kaiser San Rafael-Gallinas
San Rafael, California
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California
Mission Hope Medical Oncology - Santa Maria
Santa Maria, California
Kaiser Permanente-Santa Rosa
Santa Rosa, California
Kaiser Permanente-South San Francisco
South San Francisco, California
Saint Helena Hospital
St. Helena, California
Kaiser Permanente-Stockton
Stockton, California
Northbay Cancer Center
Vacaville, California
Kaiser Permanente Medical Center-Vacaville
Vacaville, California
Kaiser Permanente-Vallejo
Vallejo, California
Kaiser Permanente-Walnut Creek
Walnut Creek, California
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado
Showing 40 of 414 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.